GNTA
Genenta ScienceGNTA
GNTA
$4.14
13.31%
Market Cap: $75.3M
About: Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
Employees: 14
0
Funds holding %
of 6,686 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 4 [Q1] → 4 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
1.26% less ownership
Funds ownership: 2.61% [Q1] → 1.35% (-1.26%) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
57% less capital invested
Capital invested by funds: $1.74M [Q1] → $756K (-$984K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for GNTA.